GenomicMD develops a genomics risk assessment platform that utilizes population-based screening and individualized relative risk scoring to identify genomic risks for diseases such as cancer, diabetes, and cardiovascular conditions. This technology enables physicians to provide personalized clinical risk assessments, empowering patients to take proactive measures for better health outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of assessing disease risk often rely on family history and single-gene mutation analysis, which can miss a significant portion of individuals with increased risk due to the complex interplay of multiple common genetic variants. Many patients are unable to accurately provide their family history, and single-gene mutations are relatively rare in the general population. This can lead to delayed or missed opportunities for early detection and preventative care.
Solution
GenomicMD offers a Lifetime Genomics Risk Assessment (LGRA) that analyzes millions of common genetic variants to predict an individual's risk for developing common diseases such as cancer, cardiovascular disease, diabetes, and Alzheimer's. The test utilizes polygenic risk scores (PRS) to provide a more comprehensive risk assessment compared to traditional methods. By identifying individuals with an increased genomic predisposition to disease, GenomicMD enables physicians to provide personalized and proactive screening, intervention, and lifestyle suggestions to improve long-term health outcomes. The LGRA is ordered by a physician and typically involves a saliva or blood sample, with results available in 2-4 weeks.
Target Audience
The primary target audience includes physicians (oncologists, cardiologists, endocrinologists, primary care physicians) seeking to improve patient outcomes through personalized and proactive risk assessment, as well as payers and employers looking to lower healthcare costs through early disease detection and prevention.
Features
- Analyzes millions of common genetic variants using a saliva or blood sample.
- Generates a polygenic risk score (PRS) for various common diseases, including breast, prostate, colorectal, and ovarian cancer; coronary artery disease and venous thromboembolism; Type 1 and Type 2 diabetes; and Alzheimer's disease.
- Provides a comprehensive risk assessment that considers the cumulative effect of multiple genetic variants.
- Offers a provider portal for easy ordering and access to automated reporting.
- Integrates seamlessly into clinical workflows with at-home sample collection options.
- Includes training resources for doctors, nurses, physician assistants, and other clinical staff to facilitate the integration of genomics into clinical practice.
- Identifies 2-4x more at-risk patients compared to family history alone.